| Literature DB >> 36186406 |
Brett D McLarney1, Simo Huang1, Sylvia Hsu1.
Abstract
Entities:
Keywords: IBD, inflammatory bowel disease; PG, pyoderma gangrenosum; PPG, peristomal pyoderma gangrenosum; peristomal pyoderma gangrenosum; peristomal ulcers
Year: 2022 PMID: 36186406 PMCID: PMC9522867 DOI: 10.1016/j.jdcr.2022.08.040
Source DB: PubMed Journal: JAAD Case Rep ISSN: 2352-5126
Delphi criteria for diagnosing PG∗†
| Major criterion |
| Biopsy with neutrophilic infiltrate |
| Minor criteria |
| Exclusion of infection on histology |
| Pathergy |
| Personal history of IBD or inflammatory arthritis |
| Papule, pustule, or vesicle that rapidly ulcerates |
| Peripheral erythema, undermining border, and tenderness at the site of ulceration |
| Multiple ulcerations (at least 1 occurring on an anterior lower leg) |
| Cribriform or wrinkled paper scars at healed ulcer sites |
| Decrease in ulcer size within 1 month after immunosuppressive treatment |
IBD, Inflammatory bowel disease.
In the Delphi exercise, a threshold of 1 major criterion and 4 of 8 minor criteria maximized diagnostic discrimination.
Table adapted from Maverakis et al.
Fig 1Patient’s peristomal ulcer (A) at the time of presentation and (B) 10 months after the initial presentation, following debridement, closure, and wound care managed by a plastic surgery team.
Peristomal skin pathology that can mimic PPG∗
| Trauma |
| Infection or abscess |
| Ischemia |
| Hidradenitis suppurativa |
| Contact dermatitis from ostomy appliance or leakage |
| Drug-induced or exogenous tissue injury |
| Drug-induced lupus |
| Hydroxyurea induced |
| Injection drug abuse |
| Brown recluse spider bite |
| Factitious |
| Folliculitis |
| Hematoma |
| Cutaneous inflammatory bowel disease |
| Early enterocutaneous fistula formation |
| Vasculitis |
| Necrotizing fasciitis |
| Progressive bacterial synergistic gangrene |
| Autoimmune blistering disease |
| Malignancy |
| Other neutrophilic dermatoses |
| Sweet syndrome |
| Panniculitis |
| Acneiform lesions |
PPG, Peristomal pyoderma gangrenosum.
Table adapted from Afifi et al.
Reported cases and characteristics of PPG in urine-carrying ostomies
| Case | Age, sex | Time to ulcer onset | Underlying disease | Stoma type | Biopsy | Effective treatment (time to resolution) |
|---|---|---|---|---|---|---|
| 0 | 70, M | 1 mo | Bladder cancer | Ileal loop urinary diversion | Granulation tissue | Surgical debridement and closure followed by wound care (10 mo) |
| 1 | 83, M | 20 y | Bladder cancer | Urostomy | Nonspecific inflammatory infiltrate | Triamcinolone acetonide, topical clobetasol (1.5 mo) |
| 2 | 73, M | 11 mo | Bladder cancer | Urostomy | Nonspecific inflammatory infiltrate | 1st occurrence: dapsone (11 mo) |
| 3 | 45, F | 5 wk | Neurogenic bladder | Urostomy | Granulation tissue | Tacrolimus 0.3% in carmellose sodium paste (1 mo) |
| 4 | 57, F | 1 y | Bladder cancer | Urostomy | Granulation tissue | Minocycline twice daily while weaning the patient’s dose of daily prednisolone from 30 mg to 0 mg (1.5 mo) |
| 5 | 57 F | 3 y | Neurogenic bladder | Urostomy | Not performed | 2 months of no treatment followed by clobetasol propionate 0.05% for 2 weeks (2.5 mo) |
PPG, Peristomal pyoderma gangrenosum.
Denotes the patient in our case report.
Extent of improvement shown in Fig 1, B. Wound care regimen: silver sulfate foam bandages, sodium chlor-hypochlorous acid 0.033% solution, and daily collagenase ointment.